Alnylam Pharmace. buy BiotechBee
Start price
07.09.22
/
70%
€208.80
Target price
31.12.24
€300.00
Performance (%)
-33.62%
Price
17:02
€138.60
Summary
This prediction is currently active. The BUY prediction by BiotechBee for Alnylam Pharmace. is performing very badly with a performance of -33.62%. This prediction currently runs until 31.12.24. The prediction end date can be changed by BiotechBee at any time. BiotechBee has 70% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -1.381% | -1.381% | -26.633% |
| iShares Core DAX® | -0.051% | 4.829% | 17.062% |
| iShares Nasdaq 100 | 1.659% | 2.417% | 38.705% |
| iShares Nikkei 225® | 0.658% | -2.173% | 13.159% |
| iShares S&P 500 | 0.964% | 2.547% | 30.492% |
According to BiotechBee what are the pros and cons of Alnylam Pharmace. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy mit Kursziel 300,0